1.	AZD6244 and Sorafenib in Advanced Hepatocellular Carcinoma Phase: Phase II, Phase I Type: Treatment Status: Closed Age: 21 and over Sponsor: Other Protocol IDs: 09-20-HEP, NCT01029418
2.	ABC-04 a Study of Cisplatin, Gemcitabine and Selumetinib in Patients With Advanced Biliary Tract Cancer Phase: Phase II, Phase I Type: Biomarker/Laboratory analysis, Treatment Status: Closed Age: 18 and over Sponsor: Other Protocol IDs: ABC-04, 2010-018522-39, NCT01242605
3.	AZD6244 Versus Pemetrexed (Alimta®) in Patients With Non-Small Cell Lung Cancer, Who Have Failed One or Two Prior Chemotherapy Regimen Phase: Phase II Type: Treatment Status: Completed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: D1532C00012, NCT00372788
4.	AZD6244 vs. Capecitabine (Xeloda®) in Patients With Advanced or Metastatic Pancreatic Cancer, Who Have Failed First Line Gemcitabine Therapy Phase: Phase II Type: Treatment Status: Completed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: D1532C00008, NCT00372944
5.	Selumetinib in Treating Woman With Recurrent Low-Grade Ovarian Cancer or Peritoneum Cancer Phase: Phase II Type: Biomarker/Laboratory analysis, Treatment Status: Closed Age: Over 18 Sponsor: NCI Protocol IDs: NCI-2009-00604, GOG-0239, U10CA027469, NCT00551070
6.	Selumetinib in Treating Patients With Biliary Cancer That Cannot Be Removed By Surgery Phase: Phase II Type: Biomarker/Laboratory analysis, Treatment Status: Closed Age: 18 and over Sponsor: NCI Protocol IDs: NCI-2009-00251, OSU 07056, CDR0000573452, N01CM62208, N01CM62207, 07056, 7932, NCT00553332
7.	AZD6244 in Treating Patients With Papillary Thyroid Cancer That Did Not Respond to Radioactive Iodine Phase: Phase II Type: Biomarker/Laboratory analysis, Treatment Status: Closed Age: 18 and over Sponsor: NCI Protocol IDs: NCI-2009-01056, LOI 7918, N01CM62201, N01CM62203, N01CM62208, MCC-15305, MCC-LOI-7918, 7918, NCT00559949
8.	Selumetinib in Treating Patients With Recurrent or Refractory Acute Myeloid Leukemia Phase: Phase II Type: Biomarker/Laboratory analysis, Treatment Status: Closed Age: 18 and over Sponsor: NCI Protocol IDs: NCI-2009-00250, 15455B, N01CM62209, N01CM62201, UCCRC-15455B, 7925, NCT00588809
9.	MEK Inhibitor AZD6244 in Treating Patients With Stage III or Stage IV Melanoma Phase: Phase II Type: Biomarker/Laboratory analysis, Treatment Status: Closed Age: 18 and over Sponsor: NCI Protocol IDs: NCI-2009-01164, 09-003, MSKCC-09003, CDR0000637669, N01CM62206, 8252, NCT00866177
10.	AZD6244 in Cancers With BRAF Mutations Phase: Phase II Type: Treatment Status: Closed Age: 18 and over Sponsor: NCI Protocol IDs: NCI-2013-00576, DFCI 09-005, U01CA062490, N01CM62206, NCT00888134
11.	Comparison of AZD6244 in Combination With Docetaxel Versus Docetaxel Alone in KRAS Mutation Positive Non Small Cell Lung Cancer (NSCLC) Patients Phase: Phase II Type: Treatment Status: Closed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: D1532C00016, NCT00890825
12.	Comparison of AZD6244 in Combination With Dacarbazine Versus (vs) Dacarbazine Alone in BRAF Mutation Positive Melanoma Patients Phase: Phase II Type: Treatment Status: Closed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: D1532C00006, NCT00936221
13.	Selumetinib in Treating Patients With Recurrent or Persistent Endometrial Cancer Phase: Phase II Type: Biomarker/Laboratory analysis, Treatment Status: Closed Age: 18 and over Sponsor: NCI Protocol IDs: NCI-2011-01958, GOG-0229H, U10CA027469, NCT01011933
14.	Selumetinib in Treating Patients With Multiple Myeloma Phase: Phase II Type: Treatment Status: Closed Age: 18 and over Sponsor: NCI Protocol IDs: NCI-2012-02929, NCI-8631, N01CM00071, N01CM00100, NCT01085214
15.	Study of Selumetinib (AZD6244)(ARRY-142886) in Combination With Irinotecan in Previously Treated Patients With Colorec Phase: Phase II Type: Treatment Status: Completed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: D9010C00009, AGICC 09CRC02, NCT01116271
16.	Fulvestrant With or Without AZD6244 in Treating Patients With Advanced Breast Cancer That Progressed After Aromatase Inhibitor Therapy Phase: Phase II Type: Tissue collection/Repository, Treatment Status: Closed Age: Postmenopausal Sponsor: Other Protocol IDs: SAKK 21/08, SWS-SAKK-21/08, EUDRACT-2010-019965-27, EU-21046, CDR0000680800, NCT01160718
17.	MEK Inhibitor AZD6244 With or Without Temsirolimus in Treating Patients With Metastatic, Recurrent, or Locally Advanced Soft Tissue Sarcoma That Cannot Be Removed By Surgery Phase: Phase II Type: Treatment Status: Closed Age: Over 18 Sponsor: NCI Protocol IDs: NCI-2011-02532, PHII-95, N01CM62209, CHNMC-PHII-95, NCCN-T06, 8412, NCT01206140
18.	Docetaxel With or Without AZD6244 in Melanoma Phase: Phase II Type: Treatment Status: Closed Age: 16 and over Sponsor: Other Protocol IDs: OCTO_015, NCT01256359
19.	AZD6244 (ARRY-142886) Solid Oral Dosage Formulation in Patients With Advanced Solid Malignancies Phase: Phase I Type: Treatment Status: Closed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: D1532C00005, NCT00463814
20.	A Phase I, Open-Label, Multi-center Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD6244 (ARRY-142886) Phase: Phase I Type: Treatment Status: Closed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: D1532C00004, NCT00600496
21.	Study to Assess the Effect of Dosing AZD6244 HydSulfate in the Presence and Absence of Food in Patients With Advanced Solid Malignancies Phase: Phase I Type: Treatment Status: Completed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: D1532C00020, 2007-004456-37 EudraCT Number, NCT00710515
22.	A Combination Therapy Study of MK2206 and AZD6244 in Participants With Advanced Solid Tumors (MK-2206-010 AM6) Phase: Phase I Type: Treatment Status: Closed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: 2206-010, 2009_698, NCT01021748
23.	Selumetinib and Cixutumumab in Treating Patients With Advanced Solid Malignancies Phase: Phase I Type: Biomarker/Laboratory analysis, Treatment Status: Closed Age: 18 and over Sponsor: NCI Protocol IDs: NCI-2012-02912, J0961, NA_00028512, U01CA070095, NCT01061749
24.	Selumetinib and Cetuximab in Treating Patients With Refractory Solid Tumors Phase: Phase I Type: Biomarker/Laboratory analysis, Treatment Status: Closed Age: 18 and over Sponsor: NCI Protocol IDs: NCI-2012-02915, CO10901, U01CA062491, CDR0000686619, WCCC-CO-10901, 8627, NCT01217450
25.	AZD6244 With Cetuximab for Solid Tumors and Colorectal Cancer Phase: Phase I Type: Biomarker/Laboratory analysis, Treatment Status: Closed Age: 15 and over Sponsor: NCI Protocol IDs: 110075, 11-C-0075, NCT01287130